[This corrects the article DOI: 10.2147/OTT.S187306.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359784 | PMC |
| http://dx.doi.org/10.2147/OTT.S382501 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: (Thio)chromenone derivatives exhibit anti-metastatic effects through selective inhibition of uPAR in cancer cell lines: discovery of an uPAR-targeting fluorescent probe.
Chem Commun (Camb)
January 2025
Center for Metareceptome Research, Graduate School of Pharmaceutical Sciences, Chung-Ang University, 84 Heukseok-ro, Dongjak, Seoul 06974, Republic of Korea.
Correction for '(Thio)chromenone derivatives exhibit anti-metastatic effects through selective inhibition of uPAR in cancer cell lines: discovery of an uPAR-targeting fluorescent probe' by So-Young Chun , , 2025, https://doi.org/10.1039/D4CC05907G.
View Article and Find Full Text PDFCorrigendum to "Novel spirooxindole based benzimidazole scaffold: In vitro, nanoformulation and in vivo studies on anticancer and antimetastatic activity of breast adenocarcinoma" [Bioorg. Chem. 129 (2022) 106124].
Bioorg Chem
February 2024
Department of Chemistry, Faculty of Science, Mansura University, Mansura 35516, Egypt.
Author Correction: The RhoA dependent anti-metastatic function of RKIP in breast cancer.
Sci Rep
July 2023
Department of Cancer Biology, College of Medicine and Life Sciences, University of Toledo, Health Science Campus, Toledo, OH, 43614, USA.
Correction to: Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma.
J Exp Clin Cancer Res
March 2022
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!